Condition
Pleural Mesothelioma Malignant clinical trials and research
Research outlook What's coming for Mesothelioma: the next 6 months to 5 yearsAs of November 12, 2026, Find a Trial lists 2 Pleural Mesothelioma Malignant clinical trials that are recruiting, at sites in 2 countries (most in United States (1), Italy (1)). By phase: Phase 1/2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 2Clinical trials
- 2Countries
All recruiting trials (2)
-
Identifying biomarkers for toxicity in malignant pleural mesothelioma patients treated with radiotherapy
This study is trying to find specific markers in the blood that can help predict if patients with malignant pleural mesothelioma will experience serious side effects from high-dose radiotherapy combined with immune treatments.
-
Evaluating TT-10 and TT-4 for advanced solid tumors
This study is testing two new drugs, TT-10 and TT-4, to see if they are safe and effective for people with advanced solid tumors who haven't had success with other treatments.
Related topics
Quick answers
How many Pleural Mesothelioma Malignant clinical trials are recruiting right now?
2, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 2 countries. The most sites are in United States (1 trial), Italy (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.